Ceftazidime received its initial approval from the U.S. Food and Drug Administration (FDA) in December 1985. It was granted approval for various formulations and indications to treat bacterial infections caused by susceptible organisms.

Ceftazidime is used to treat various bacterial infections caused by susceptible organisms, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and intra-abdominal infections.

Ceftazidime is typically administered via injections in hospital settings by a healthcare professional. The dosage and frequency of administration depend on the severity of the infection, the patient's age, and kidney function.

Ceftazidime, like other antibiotics, may cause side effects in some individuals. Common side effects include nausea, vomiting, diarrhea, rash, itching, headache, and pain at the injection site (for intravenous use). Serious side effects may include severe allergic reactions (anaphylaxis), Clostridium difficile-associated diarrhea (CDAD), liver problems, and kidney problems.

Ceftazidime carries several warnings that should be considered before use. Serious allergic reactions, including anaphylaxis, can necessitate immediate medical attention if symptoms like difficulty breathing or facial swelling occur. The medication may also lead to Clostridium difficile-associated diarrhea, a severe gastrointestinal infection. Overusing this medication can contribute to antibiotic resistance, and periodic monitoring of bacterial susceptibility is essential. Additionally, the drug may cause blood disorders, electrolyte imbalances, and inflammation at the injection site. 

Patients with a history of allergic reactions to cephalosporins or penicillins should exercise caution, and liver and kidney function should be monitored in patients with impaired organ function. Before using Ceftazidime, inform your healthcare professional about any known allergies, glaucoma, gastrointestinal disorders, urinary retention, cardiovascular conditions, heat stroke risk, renal or hepatic impairment, pregnancy, breastfeeding, and all medications or supplements you are taking. Exercise caution when driving or operating machinery due to potential CNS effects. Regular monitoring and consultation with a healthcare professional are important for personalized guidance and to ensure the safe and effective use of Ceftazidime. Proper central venous catheter care is necessary to prevent catheter-related infections. In cases of severe or persistent side effects, patients should promptly seek medical attention.

Patients with a history of allergies to cephalosporin or penicillin antibiotics should inform their healthcare provider to avoid potential allergic reactions. It is essential to complete the full course of treatment as prescribed, even if symptoms improve, to prevent antibiotic resistance. Ceftazidime can disrupt normal gut flora, leading to Clostridium difficile-associated diarrhea, so any signs of persistent diarrhea should be reported to the healthcare provider. Patients with impaired kidney or liver function may require dose adjustments or close monitoring. 

Since this medication can affect electrolyte levels, careful monitoring may be necessary, especially in high-risk patients. Use during pregnancy and breastfeeding requires careful evaluation by a healthcare professional to balance potential risks and benefits. Caution should be exercised in patients with central venous catheters to prevent catheter-related infections. Patients should promptly report any unusual or severe side effects to their healthcare provider.

1. KD Tripathi, Essentials of Medical Pharmacology, Beta-Lactam Antibiotics, 7th edition, 2013,728.
2. Goodman & Gilman’s, The Pharmacological Basics of Therapeutics, Penicillins, Cephalosporins and other Beta-Lactam Antibiotics, 12th edition, 2011, 1498.
3. B. Braun Medical Inc., US Food and Drug Administration, [ Revised on October 2021] [ Accessed on 9th April 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050823s009lbl.pdf.
4. Wockhardt UK Ltd, Electronic medicines compendium (EMC), [ Revised on 16 Aug 2021] [ Accessed on 9th April], https://www.medicines.org.uk/emc/files/pil.6346.pdf 

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.